The impact of disease burden: Understanding patient priorities in aRCC

Understanding patient expectations and clinicians' goals in favourable risk aRCC patients

Combination therapeutic strategies for aRCC patients with bone metastases

Non-clear cell renal cell carcinoma: Management of papillary RCC

Treatment management of favourable risk and very favourable risk patients

Managing cardiotoxicities for RCC treatment – Cardiologist’s perspective

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective

CaboNivo shows sustained long-term benefits for survival and tumour progression as a 1L treatment of aRCC

Repeat immune checkpoint inhibitor therapy not recommended for aRCC

Durable responses in aRCC, how do we optimise treatment?

Patient expectations and shared decision making in aRCC

Lenvatinib and pembrolizumab show promising efficacy in first-line treatment of aRCC